News Sentiment

PALI sentiment intelligence

Palisade Bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.96 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 36

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-6.7% over one week, +14.6% over four weeks, trend active, and below fair value.

Latest direct headline Positive

Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction -6.7% Price reacting lower
Trend fit Trend active 14.6% over four weeks
Fair value -52.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 29
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 36
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 7
GlobeNewswire 6
TradingView 5
Investing.com Nigeria 5
Investing.com 4
simplywall.st 3
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 14
Deals and strategy 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 45
Investing.com Direct company coverage

Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock

Palisade Bio director Robert Baltera Jr. recently purchased $88,698 worth of the company's common stock through multiple transactions on July 8 and 9, 2026, increasing his direct ownership to 461,904 shares. These insider purchases follow the company's stock delivering a 151% ret

Tone
Positive 71/100
Event
Market update
Published
11 Jul 2026 20:11
Source
Investing.com
TradingView Direct company coverage

Enterprise value to revenue forward of Palisade Bio, Inc. – LS:A4098S

The article provides financial information for Palisade Bio, Inc. (A4098S) on TradingView, specifically focusing on its enterprise value to revenue forward. It appears to be a financial data page from the platform, indicating the market status, and offering various financial tool

Tone
Neutral 50/100
Event
Earnings
Published
11 Jul 2026 15:09
Source
TradingView
GlobeNewswire Direct company coverage

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

Palisade Bio, a clinical-stage biopharmaceutical company, announced that its CEO, JD Finley, and President & Chief Medical Officer, Dr. Mitchell Jones, will attend the Leerink Partners Therapeutics Forum on July 14-15, 2026, in Boston. They plan to meet with institutional investo

Tone
Positive 64/100
Event
Market update
Published
11 Jul 2026 09:42
Source
GlobeNewswire
Investing.com Nigeria Direct company coverage

Form 4 Palisade Bio Inc For: 10 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Palisade Bio Inc (PALI) dated July 10. The filing indicates some sort of insider transaction or change in ownership, though specific details are not provided beyond the date and the company name. The article also incl

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 08:10
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Palisade Bio (PALI) director adds 45,000 shares through July open-market buys

Palisade Bio director Robert Baltera Jr. made two open-market purchases of common stock in July 2026, acquiring a total of 45,000 shares. These transactions increased his direct holdings to 461,904 shares, signaling positive sentiment towards the company. The purchases were execu

Tone
Positive 69/100
Event
Market update
Published
11 Jul 2026 07:40
Source
Stock Titan
Pluang Direct company coverage

Palisade Bio to present clinical updates at Leerink Partners Therapeutics Forum in July 2026

Palisade Bio, a clinical-stage biopharmaceutical company, announced that its CEO and President will attend the Leerink Partners Therapeutics Forum in July 2026. They will engage in one-on-one meetings with investors to discuss the company's clinical development strategy and the p

Tone
Positive 72/100
Event
Market update
Published
10 Jul 2026 13:40
Source
Pluang
Stock Titan Direct company coverage

Palisade Bio leaders set to outline IBD drug plans at Boston forum

Palisade Bio (Nasdaq: PALI) announced that its CEO and President & CMO will participate in the Leerink Partners Therapeutics Forum on July 14-15, 2026, in Boston. They plan to hold one-on-one meetings with institutional investors to discuss the company's clinical development stra

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 12:40
Source
Stock Titan
Seeking Alpha Direct company coverage

Palisade Bio Stock: A Unique MoA Targeting The UC And Crohn’s Disease Markets (PALI)

Palisade Bio (PALI) presents a speculative, early-stage investment opportunity with PALI-2108, a gut-restricted PDE4 inhibitor for UC and Crohn’s disease, having shown promising Phase 1 results. The company's $132.6 million cash runway provides funding through key Phase 2 readout

Tone
Positive 70/100
Event
Earnings
Published
10 Jul 2026 07:06
Source
Seeking Alpha
Investing.com Nigeria Direct company coverage

Palisade Bio CEO, CFO Finley sells $303k in stock By Investing.com

Palisade Bio's CEO and CFO, John David Finley, sold 146,798 shares totaling $303,343 to cover tax obligations from vested restricted stock units, despite the stock's 184% return over the past year. Earlier, Finley acquired 335,167 shares from RSU settlements and 133 shares from w

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 23:45
Source
Investing.com Nigeria
Investing.com Nigeria Direct company coverage

Palisade Bio chief medical officer Jones sells $106,535 in stock

Palisade Bio's Chief Medical Officer, Mitchell Lawrence Jones, sold 51,880 shares of company stock for $106,535 to cover tax obligations from vested Restricted Stock Units (RSUs). Prior to this sale, he acquired 131,167 shares through RSU settlements, and he now holds 94,009 shar

Tone
Negative 41/100
Event
Market update
Published
09 Jul 2026 07:11
Source
Investing.com Nigeria
Investing.com Nigeria Direct company coverage

Form 4 Palisade Bio Inc For: 8 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Palisade Bio Inc, dated July 8th. Form 4s disclose transactions made by company insiders. The article indicates that Palisade Bio Inc (PALI) experienced a -4.15% change in its stock.

Tone
Negative 41/100
Event
Market update
Published
08 Jul 2026 23:45
Source
Investing.com Nigeria
Investing.com South Africa Direct company coverage

Palisade Bio chief medical officer Jones sells $106,535 in stock By Investing.com

Mitchell Lawrence Jones, Chief Medical Officer of Palisade Bio, sold 51,880 shares of the company's common stock for $106,535 to cover tax withholding obligations. This sale followed his acquisition of 131,167 shares through vested Restricted Stock Units. The company recently rec

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 23:40
Source
Investing.com South Africa
Investing.com Direct company coverage

Palisade Bio director Robert Baltera Jr. buys $102,084 in stock

Palisade Bio director Robert Baltera Jr. purchased $102,084 worth of company stock across two days, acquiring 50,000 shares in total, bringing his direct holdings to 416,904 shares. This insider buying occurs as PALI shares have seen a significant annual surge but are down year-t

Tone
Positive 67/100
Event
Market update
Published
08 Jul 2026 23:40
Source
Investing.com
Stock Titan Direct company coverage

Palisade Bio (PALI) CEO Finley sells shares to cover RSU tax

Palisade Bio (PALI) CEO and CFO John David Finley reported a routine equity compensation activity, including the vesting of Restricted Stock Units (RSUs) and a small warrant exercise. Finley acquired 335,167 common

Tone
Negative 39/100
Event
Market update
Published
08 Jul 2026 22:40
Source
Stock Titan
Stock Titan Direct company coverage

Director at Palisade Bio (PALI) adds 50,000 shares in open-market buys

Palisade Bio director Robert Baltera Jr. recently purchased 50,000 shares of common stock in open-market transactions over two days. These purchases, totaling over $102,000, increased his direct ownership to 416,904 shares. The transactions underscore a positive sentiment from an

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 22:40
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] PALISADE BIO, INC. Insider Trading Activity

This article details the insider trading activity of Mitchell Lawrence Jones, Chief Medical Officer of Palisade Bio, Inc. (PALI), as reported in a Form 4 SEC filing. The activity primarily involves the exercise of restricted stock units (RSUs) and a subsequent sale of shares to c

Tone
Negative 41/100
Event
Market update
Published
08 Jul 2026 22:40
Source
Stock Titan
Simply Wall Street Direct company coverage

Insider Spends US$59k Buying More Shares In Palisade Bio

Palisade Bio's Independent Director, Robert Baltera, recently purchased US$59k worth of company stock, increasing his shareholding by 8.9%. This insider buying activity, the largest in the past year, suggests optimism about the company despite its current losses and low overall i

Tone
Positive 64/100
Event
Market update
Published
08 Jul 2026 10:39
Source
Simply Wall Street
Investing.com Nigeria Direct company coverage

Form 144 PALISADE BIO For: 7 July By Investing.com

Investing.com reported on Form 144 for PALISADE BIO on July 7th. The article is a brief financial update indicating the filing of a Form 144, which relates to the proposed sale of restricted securities. It also includes general market data and other news.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 22:04
Source
Investing.com Nigeria
Investing.com Direct company coverage

Palisade Bio director Robert Baltera Jr. buys $59,400 in stock

Robert Baltera Jr., a director at Palisade Bio (NASDAQ:PALI), recently purchased 30,000 shares of company stock for $59,400, bringing his total direct holdings to 366,904 shares. This insider buying follows the FDA's clearance for Palisade Bio's Phase 2 clinical trial of PALI-210

Tone
Positive 67/100
Event
Market update
Published
07 Jul 2026 00:41
Source
Investing.com
Stock Titan Direct company coverage

Palisade Bio (PALI) director adds 30,000 shares in open-market buys

Palisade Bio director Robert Baltera Jr. recently purchased 30,000 shares of the company's common stock through open-market transactions at a weighted average price of $1.98 per share. These purchases, totaling $59,400, have increased his direct holdings to 366,904 shares, signal

Tone
Positive 72/100
Event
Market update
Published
06 Jul 2026 23:41
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Palisade Bio Inc For: 6 July By Investing.com

The article reports that Palisade Bio Inc. filed a Form 4 for July 6th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their ownership of company stock. The article provides minimal details b

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 23:41
Source
Investing.com Canada
TradingView Direct company coverage

Price to book forward of Palisade Bio, Inc. – NASDAQ:PALI

This article focuses on the "Price to book forward" financial metric for Palisade Bio, Inc. (NASDAQ: PALI). It appears to be a financial data point provided by TradingView, without additional analysis or details. The content is primarily a data placeholder within a financial plat

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 08:42
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Palisade Bio, Inc. – NASDAQ:PALI

This article provides a brief snapshot of Palisade Bio, Inc. (NASDAQ: PALI) on TradingView, focusing on its financial overview. It mentions the company's stock information, market status, and available financial data. The content is primarily a data placeholder, indicating a lack

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 18:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Palisade Bio, Inc. – BOATS:PALI

This article focuses on the enterprise value to revenue forward for Palisade Bio, Inc. (PALI), traded on the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data point or analysis available on the TradingView platform, with no further detailed content pr

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 03:01
Source
TradingView